Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 3
1976 7
1977 2
1978 5
1979 8
1980 7
1981 5
1982 11
1983 15
1984 18
1985 16
1986 20
1987 22
1988 30
1989 34
1990 49
1991 59
1992 59
1993 100
1994 103
1995 130
1996 155
1997 130
1998 156
1999 181
2000 167
2001 235
2002 206
2003 247
2004 251
2005 242
2006 276
2007 306
2008 295
2009 338
2010 365
2011 446
2012 456
2013 489
2014 544
2015 486
2016 596
2017 590
2018 669
2019 637
2020 705
2021 784
2022 706
2023 672
2024 199

Text availability

Article attribute

Article type

Publication date

Search Results

10,970 results

Results by year

Filters applied: . Clear all
Page 2
Ongoing phase I and II studies of novel anthracyclines.
Sessa C, Valota O, Geroni C. Sessa C, et al. Cardiovasc Toxicol. 2007;7(2):75-9. doi: 10.1007/s12012-007-0010-8. Cardiovasc Toxicol. 2007. PMID: 17652808 Review.
Many anthracyclines are currently in clinical development with the common aim of improving selectivity. This could be achieved by improving tumor drug delivery through the identification and development of molecules with new structure, prodrugs with low molecular we …
Many anthracyclines are currently in clinical development with the common aim of improving selectivity. This could be achieved by …
An update on bronchodilators in Phase I and II clinical trials.
Cazzola M, Rogliani P, Segreti A, Matera MG. Cazzola M, et al. Expert Opin Investig Drugs. 2012 Oct;21(10):1489-501. doi: 10.1517/13543784.2012.710602. Epub 2012 Aug 23. Expert Opin Investig Drugs. 2012. PMID: 22916733 Review.
Therefore, there is still considerable interest in finding novel classes of broncholytic drugs or, at least, in improving the existing classes of bronchodilator. AREAS COVERED: This review paper mainly focuses on bronchodilators that are in Phase I and II cli …
Therefore, there is still considerable interest in finding novel classes of broncholytic drugs or, at least, in improving the existin …
Enhancing phase I dose-finding trials design through dynamic borrowing information and handling late-onset toxicity.
Yang W, He R, Sun Y, Yan F, Wang F. Yang W, et al. Front Pharmacol. 2023 Nov 22;14:1266322. doi: 10.3389/fphar.2023.1266322. eCollection 2023. Front Pharmacol. 2023. PMID: 38074153 Free PMC article.
Introduction: In recent years, there has been a growing trend among regulatory agencies to consider the use of historical controls in clinical trials as a means of improving the efficiency of trial design. In this paper, to enhance the statistical operating characteristic …
Introduction: In recent years, there has been a growing trend among regulatory agencies to consider the use of historical controls in clinic …
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Hubbard JM, Yin J, Schenk EL, Qin R, Reid JM, Strand C, Fiskum J, Menefee M, Lin G, Doyle LA, Ivy P, Erlichman C, Adjei A, Haluska P, Costello BA. Hubbard JM, et al. Invest New Drugs. 2022 Feb;40(1):115-123. doi: 10.1007/s10637-021-01175-6. Epub 2021 Sep 13. Invest New Drugs. 2022. PMID: 34515877 Free PMC article. Clinical Trial.
This phase I trial was designed to test the two agents in combination to evaluate the tolerability, safety and assess disease response. METHODS: Patients with advanced solid malignancies were enrolled into this phase I trial. Cediranib and selumetinib …
This phase I trial was designed to test the two agents in combination to evaluate the tolerability, safety and assess disease …
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience.
Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Goldstein JB, et al. Oncotarget. 2017 Aug 3;8(50):87163-87173. doi: 10.18632/oncotarget.19897. eCollection 2017 Oct 20. Oncotarget. 2017. PMID: 29152071 Free PMC article.
We sought to determine the impact of novel therapeutics on PC patients in phase I trials. METHODS: We reviewed records of PC patients treated in phase I trials at our institution from January 2009 through December 2014. ...Three patients had partial re …
We sought to determine the impact of novel therapeutics on PC patients in phase I trials. METHODS: We reviewed records of PC p …
Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer.
Henke LE, Stanley JA, Robinson C, Srivastava A, Contreras JA, Curcuru A, Green OL, Massad LS, Kuroki L, Fuh K, Hagemann A, Mutch D, McCourt C, Thaker P, Powell M, Markovina S, Grigsby PW, Schwarz JK, Chundury A. Henke LE, et al. Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):379-389. doi: 10.1016/j.ijrobp.2021.08.033. Epub 2021 Aug 30. Int J Radiat Oncol Biol Phys. 2022. PMID: 34474109 Clinical Trial.
This phase I trial assessed feasibility, safety, and dosimetric advantage of SMART to treat ovarian oligometastases. ...Median Kaplan-Meier estimated systemic-therapy-free survival after radiation completion was 11.5 months, with concomitant quality-of-life impro
This phase I trial assessed feasibility, safety, and dosimetric advantage of SMART to treat ovarian oligometastases. ...Median …
Phase I Single-Blinded Randomized Controlled Trial Comparing Balance and Aerobic Training in Degenerative Cerebellar Disease.
Barbuto S, Martelli D, Isirame O, Lee N, Bishop L, Kuo SH, Agrawal S, Lee S, O'Dell M, Stein J. Barbuto S, et al. PM R. 2021 Apr;13(4):364-371. doi: 10.1002/pmrj.12401. Epub 2020 May 29. PM R. 2021. PMID: 32383352 Free PMC article. Clinical Trial.
OBJECTIVE: To determine the feasibility of conducting a randomized trial comparing balance and aerobic training in individuals with cerebellar degeneration. DESIGN: Assessor blinded randomized control phase I trial. SETTING: Assessments in medical center, home train …
OBJECTIVE: To determine the feasibility of conducting a randomized trial comparing balance and aerobic training in individuals with cerebell …
Advances in the Diagnosis and Treatment of Leptomeningeal Disease.
Sharma A, Low JT, Kumthekar P. Sharma A, et al. Curr Neurol Neurosci Rep. 2022 Jul;22(7):413-425. doi: 10.1007/s11910-022-01198-3. Epub 2022 May 19. Curr Neurol Neurosci Rep. 2022. PMID: 35588045 Review.
However, these studies have primarily been phase I/II and retrospective analyses. There remains a dearth of clinical trials that include LMD patients. The combination of patient-specific molecular information and novel therapeutic approaches holds significant promis …
However, these studies have primarily been phase I/II and retrospective analyses. There remains a dearth of clinical trials th …
Efficacy of ruxolitinib for myelofibrosis.
Santos FP, Verstovsek S. Santos FP, et al. Expert Opin Pharmacother. 2014 Jul;15(10):1465-73. doi: 10.1517/14656566.2014.923404. Epub 2014 May 24. Expert Opin Pharmacother. 2014. PMID: 24856675 Free PMC article. Review.
AREAS COVERED: A literature search through Medline employing the terms 'ruxolitinib,' 'INCB018424' and 'myelofibrosis' was undertaken. The results from Phase I/II studies in patients with MF showed that ruxolitinib led to durable improvements in splenomegaly, …
AREAS COVERED: A literature search through Medline employing the terms 'ruxolitinib,' 'INCB018424' and 'myelofibrosis' was undertaken. The r …
Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.
Zeidner JF, Karp JE, Blackford AL, Foster MC, Dees EC, Smith G, Ivy SP, Harris P. Zeidner JF, et al. J Natl Cancer Inst. 2015 Nov 9;108(3):djv335. doi: 10.1093/jnci/djv335. Print 2016 Mar. J Natl Cancer Inst. 2015. PMID: 26553781 Free PMC article.
RESULTS: There was a statistically significant increase in AML patients enrolling in phase I clinical trials over time (1986 to 1990: n = 61; 2006 to 2009: n = 256; P = .03). ...The 60-day mortality rate for the entire cohort was 22.6%, but it statistically signific …
RESULTS: There was a statistically significant increase in AML patients enrolling in phase I clinical trials over time (1986 t …
10,970 results
You have reached the last available page of results. Please see the User Guide for more information.